



**To:** Prestige Health Choice Network Providers

**From:** Prestige Pharmacy Department

**Date:** February 19, 2018

**Subject: Basaglar human insulin analog**

Basaglar (insulin glargine injection) is a long-acting human insulin analog that has an identical amino acid sequence to Lantus<sup>®</sup>. The safety and effectiveness of Basaglar is comparable to Lantus<sup>®</sup> as well. While Basaglar is similar in efficacy to Lantus<sup>®</sup>, the cost of Basaglar is comparatively lower.

**What you may consider doing:**

- If your patients currently use Lantus<sup>®</sup>, talk to them about Basaglar in a KwikPen<sup>®</sup>, or if you have a patient newly diagnosed with diabetes, consider initiating therapy with Basaglar.
- Prestige Health Choice will allow prescriptions for Basaglar to be paid at the point-of-sale, and does not require prior authorization for quantities  $\leq 30$  mL/month (equal to two boxes containing five pens each).
- Availability:
  - Basaglar KwikPen<sup>®</sup> (prefilled): 5 x 3 mL pens (U-100) from Eli Lilly and Co.
  - Lantus SoloStar<sup>®</sup> (prefilled): 5 x 3 mL pens (U-100) from Sanofi-Aventis.
  - Lantus<sup>®</sup> Vial: 10 mL vial (U-100) from Sanofi-Aventis.
  - The 28-day in-use stability is identical for each product.

If you have additional questions, please call PerformRx<sup>SM</sup> Pharmacy Services at **1-855-371-3963**.

Sincerely,

Sandra Schwemmer, D.O., FACOEP-D, FACEP, FAAOE, LHRM  
Chief Medical Officer